Wall Street Zen Upgrades Aethlon Medical (NASDAQ:AEMD) to “Sell”

Aethlon Medical (NASDAQ:AEMD) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Other analysts have also issued research reports about the company. HC Wainwright reissued a “neutral” rating on shares of Aethlon Medical in a report on Friday, September 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research note on Thursday. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Aethlon Medical presently has an average rating of “Reduce” and a consensus price target of $1.50.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $5.15 on Friday. The company’s 50 day moving average price is $3.98 and its 200-day moving average price is $6.70. Aethlon Medical has a 52 week low of $1.41 and a 52 week high of $29.45. The stock has a market cap of $3.66 million, a price-to-earnings ratio of -0.15 and a beta of 1.21.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share for the quarter, missing the consensus estimate of ($3.92) by ($0.10). As a group, sell-side analysts anticipate that Aethlon Medical will post -5.74 earnings per share for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc is a medical technology company focused on developing extracorporeal filtration systems designed to remove harmful biological materials from the blood. The company’s primary technology is the Hemopurifier, an investigational device intended to capture disease-related particles, including exosomes and certain viruses, during blood filtration.

The Hemopurifier is being studied for potential applications in oncology and infectious disease. In cancer research, the device is designed to remove tumor-derived exosomes, which may contribute to immune suppression and disease progression.